Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Oxford Immunotec Global PLC (NASDAQ: OXFD).

Full DD Report for OXFD

You must become a subscriber to view this report.


Recent News from (NASDAQ: OXFD)

Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc. (NASDAQ:ESPR), Oxford Immunotec Global PLC (N...
Source: GlobeNewswire
Date: August, 20 2018 07:45
Your Daily Pharma Scoop: Puma Progresses, Kala In Phase 3, Teva Fails
Stocks in the News: PBYI, KALA Puma Bio's Nerlynx marketing application in Canada under review Puma Biotechnology's ( PBYI ) New Drug Submission (‘NDS) for NERLYNX ( neratinib ) for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer is...
Source: SeekingAlpha
Date: August, 02 2018 06:35
Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2018 Results - Earnings Call Transcript
Oxford Immunotec Global PLC (OXFD) Q2 2018 Earnings Conference Call July 31, 2018, 08:00 AM ET Executives Karen Koski - Head of Strategy and IR Peter Wrighton-Smith - CEO Richard Altieri - CFO Analysts Catherine Schulte - Baird William Quirk - Piper Jeffrey Doug Schenke...
Source: SeekingAlpha
Date: July, 31 2018 13:39
Oxford Immunotec Global EPS in-line, beats on revenue
Oxford Immunotec Global (NASDAQ: OXFD ): Q2 EPS of -$0.25 in-line. More news on: Oxford Immunotec Global PLC, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 31 2018 07:03
Oxford Immunotec Reports Second Quarter 2018 Financial Results
Second quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United States Gross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basis Launch of transformative T-Cell Select™ product to enable full a...
Source: Thomson Reuters ONE
Date: July, 31 2018 07:00
Oxford Immunotec Launches T-Cell Select(TM) to Enable Full Automation of the T-SPOT®.TB Test, Provides Unrivaled Sample Stability and Simplicity of Blood Collection
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the new CE-marked T-Cell Select kit in Europe and select ROW countries. Using the T-Cell Selec...
Source: Thomson Reuters ONE
Date: July, 31 2018 06:55
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 201...
Source: GlobeNewswire
Date: July, 17 2018 08:30
Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT®.TB Test
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent tu...
Source: GlobeNewswire
Date: June, 05 2018 08:30
Investor Expectations to Drive Momentum within Oxford Immunotec Global, Financial Engines, Brookfield Property Partners, Arsanis, QIWI, and Stitch Fix - Discovering Underlying Factors of Influence
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC (NASDAQ:OXFD), Financial Engines, Inc. (NASDA...
Source: GlobeNewswire
Date: June, 05 2018 07:50
Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that data from studies utilizing the T-SPOT. CMV test will be presented at the American Transplant Congress...
Source: GlobeNewswire
Date: June, 04 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1314.8914.3616.1414.1393,351
2018-12-1215.0014.8515.2514.80110,362
2018-12-1115.0014.8415.1114.7251,185
2018-12-1014.9914.8915.0614.5971,919
2018-12-0714.9314.9815.2014.82116,476

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-133,39617,60819.2867Cover
2018-12-121,38434,8393.9726Cover
2018-12-118284,93616.7747Cover
2018-12-103,16315,57620.3069Cover
2018-12-074,17825,25816.5413Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OXFD.


About Oxford Immunotec Global PLC (NASDAQ: OXFD)

Logo for Oxford Immunotec Global PLC (NASDAQ: OXFD)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $344,478,133 - 05/11/2018
  • Issue and Outstanding: 25,881,152 - 04/25/2018

 


Recent Filings from (NASDAQ: OXFD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: OXFD)

Daily Technical Chart for (NASDAQ: OXFD)


Stay tuned for daily updates and more on (NASDAQ: OXFD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: OXFD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OXFD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OXFD and does not buy, sell, or trade any shares of OXFD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/